Abstract
INTRODUCTION: Tumor lysis syndrome (TLS) is a metabolic emergency characterized by hyperphosphatemia, hyperuricemia, hyperkalemia, hypocalcemia, and acute renal failure. This potentially fatal syndrome is most often seen after anti-cancer treatment of extensive, rapidly proliferating, and treatment-sensitive tumors such as aggressive lymphomas and acute leukemias. The pathophysiologic mechanism of TLS is thought to be rapid tumor necrosis leading to the release of intracellular ions and metabolic products into the bloodstream.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
